Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Low molecular weight heparin vs no LMWH

Thrombocytopenia · people with cancer with thrombosis prophylaxis and central venous catheters

Low‐molecular‐weight heparin (LMWH) showed no clear difference in thrombocytopenia (up to 3 months) compared with no LMWH (low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 1.03 [0.8, 1.33]
4 studies · 1002 participants
Low

Low molecular weight heparin vs vitamin K antagonist (VKA)

Thrombocytopenia (up to 3 months)n · people with cancer with thrombosis prophylaxis and central venous catheters

Low‐molecular‐weight heparin (LMWH) probably leads to higher thrombocytopenia (up to 3 months)n compared with vitamin K antagonist (VKA) (moderate certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 1.69 [1.2, 2.39]
2 studies · 327 participants
Moderate